Literature DB >> 20844611

Comparison of antimicrobial agents as therapy for experimental endocarditis: caused by methicillin-resistant Staphylococcus aureus.

Mustafa Sacar1, Suzan Sacar, Nural Cevahir, Gokhan Onem, Zafer Teke, Ali Asan, Huseyin Turgut, Fahri Adali, Ilknur Kaleli, Ibrahim Susam, Yalin Tolga Yaylali, Ahmet Baltalarli.   

Abstract

We used an experimental rat model to compare the therapeutic efficacy of teicoplanin, linezolid, and quinupristin/dalfopristin with that of vancomycin as standard therapy for infective endocarditis.Aortic endocarditis was induced in rats by insertion of a polyethylene catheter into the left ventricle, followed by intravenous inoculation of 106 colony-forming units of methicillin-resistant Staphylococcus aureus 24 hours later. Forty-eight hours after bacterial challenge, intravenous antibiotic therapies were initiated. There were 6 groups of 8 rats each: uninfected control; infected, untreated control; vancomycin-treated (40 mg/kg twice daily); teicoplanin-treated (20 mg/kg twice daily after a loading dose of 40 mg/kg); linezolid-treated (75 mg/kg 3 times daily for 1 day, then 75 mg/kg twice daily); and quinupristin/dalfopristin-treated (30 mg/kg twice daily and an additional 10 mg/kg dalfopristin infusion over 6 to 12 hr daily). At the end of therapy, the aortic valve vegetations in the drug-treated rats were evaluated microbiologically.Compared with the infected, untreated group, all drug-treated groups had significantly reduced bacterial titers in the vegetations. Vancomycin, teicoplanin, and quinupristin/dalfopristin all effectively reduced the quantitative bacterial cultures of aortic valve vegetations. In addition, there was no significant difference in the comparative efficacy of teicoplanin, linezolid, and quinupristin/dalfopristin. Vancomycin significantly reduced bacterial counts in comparison with linezolid, which was nonetheless also effective.Our experimental model showed that each of the investigated antimicrobial agents was effective in the treatment of infective endocarditis.

Entities:  

Keywords:  Anti-bacterial agents/pharmacology/therapeutic use; Staphylococcus aureus/drug effects; disease models, animal; drug resistance, microbial; endocarditis, bacterial/microbiology/drug therapy; linezolid; methicillin resistance; microbial sensitivity tests; rodents; staphylococcal infections/epidemiology; teicoplanin; vancomycin

Mesh:

Substances:

Year:  2010        PMID: 20844611      PMCID: PMC2929854     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  32 in total

1.  Staphylococcal endocarditis---recommendations for therapy.

Authors:  Ethan Rubinstein; Claude Carbon
Journal:  Clin Microbiol Infect       Date:  1998       Impact factor: 8.067

2.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

3.  Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus.

Authors:  V Zarrouk; B Bozdogan; R Leclercq; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues.

Authors:  C Martin; P Bourget; M Alaya; A Sertin; C Atlani; K Ennabli; R Said
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Vancomycin Ototoxicity in patient with normal renal function.

Authors:  P G Traber; D P Levine
Journal:  Ann Intern Med       Date:  1981-10       Impact factor: 25.391

6.  Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  Fu-Yu Chiang; Michael Climo
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

7.  Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.

Authors:  David R Murdoch; G Ralph Corey; Bruno Hoen; José M Miró; Vance G Fowler; Arnold S Bayer; Adolf W Karchmer; Lars Olaison; Paul A Pappas; Philippe Moreillon; Stephen T Chambers; Vivian H Chu; Vicenç Falcó; David J Holland; Philip Jones; John L Klein; Nigel J Raymond; Kerry M Read; Marie Francoise Tripodi; Riccardo Utili; Andrew Wang; Christopher W Woods; Christopher H Cabell
Journal:  Arch Intern Med       Date:  2009-03-09

8.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

9.  Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus.

Authors:  D P Nicolau; C D Freeman; C H Nightingale; C J Coe; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart.

Authors:  B B Perlman; L R Freedman
Journal:  Yale J Biol Med       Date:  1971-10
View more
  4 in total

1.  Engineering a soluble high-affinity receptor domain that neutralizes staphylococcal enterotoxin C in rabbit models of disease.

Authors:  D M Mattis; A R Spaulding; O N Chuang-Smith; E J Sundberg; P M Schlievert; D M Kranz
Journal:  Protein Eng Des Sel       Date:  2012-11-15       Impact factor: 1.650

2.  An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.

Authors:  Richard R Watkins; Tracy L Lemonovich; Thomas M File
Journal:  Core Evid       Date:  2012-12-11

3.  A Novel Biocompatible Titanium-Gadolinium Quantum Dot as a Bacterial Detecting Agent with High Antibacterial Activity.

Authors:  Vishma Pratap Sur; Aninda Mazumdar; Amirmansoor Ashrafi; Atripan Mukherjee; Vedran Milosavljevic; Hana Michalkova; Pavel Kopel; Lukáš Richtera; Amitava Moulick
Journal:  Nanomaterials (Basel)       Date:  2020-04-17       Impact factor: 5.076

4.  Construction of a Multiplex Promoter Reporter Platform to Monitor Staphylococcus aureus Virulence Gene Expression and the Identification of Usnic Acid as a Potent Suppressor of psm Gene Expression.

Authors:  Peng Gao; Yanli Wang; Iván Villanueva; Pak Leung Ho; Julian Davies; Richard Yi Tsun Kao
Journal:  Front Microbiol       Date:  2016-08-30       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.